|
Showing 1 - 3 of
3 matches in All Departments
Tuberculosis (TB) kills approximately 4,500 people worldwide every
day. While most cases of TB can be treated with antibiotics, some
strains have developed drug resistance that makes their treatment
more expensive, more toxic and less effective for the patient. The
IOM Forum on Drug Discovery, Development, and Translation and the
Academy of Science of South Africa held a workshop to discuss ways
to fight the growing threat of drug-resistant TB. Table of Contents
Front Matter 1 Introduction 2 The Incidence of Drug-Resistant TB in
Southern Africa 3 Surveillance and Tracking of Drug-Resistant TB 4
Transmission and Infection Control 5 Diagnosis of Drug-Resistant TB
6 Treatment of Drug-Resistant TB 7 Drug-Resistant TB in Children 8
Convergence of Science and Policy to Create a Blueprint for Action
References Appendix A: Agenda Appendix B: Report from the National
Institute of Allergy and Infectious Diseases (NIAID) Workshop
Appendix C: Participant Biographies
An ideal health care system relies on efficiently generating
timely, accurate evidence to deliver on its promise of diminishing
the divide between clinical practice and research. There are
growing indications, however, that the current health care system
and the clinical research that guides medical decisions in the
United States falls far short of this vision. The process of
generating medical evidence through clinical trials in the United
States is expensive and lengthy, includes a number of regulatory
hurdles, and is based on a limited infrastructure. The link between
clinical research and medical progress is also frequently
misunderstood or unsupported by both patients and providers. The
focus of clinical research changes as diseases emerge and new
treatments create cures for old conditions. As diseases evolve, the
ultimate goal remains to speed new and improved medical treatments
to patients throughout the world. To keep pace with rapidly
changing health care demands, clinical research resources need to
be organized and on hand to address the numerous health care
questions that continually emerge. Improving the overall capacity
of the clinical research enterprise will depend on ensuring that
there is an adequate infrastructure in place to support the
investigators who conduct research, the patients with real diseases
who volunteer to participate in experimental research, and the
institutions that organize and carry out the trials. To address
these issues and better understand the current state of clinical
research in the United States, the Institute of Medicine's (IOM)
Forum on Drug Discovery, Development, and Translation held a 2-day
workshop entitled Transforming Clinical Research in the United
States. The workshop, summarized in this volume, laid the
foundation for a broader initiative of the Forum addressing
different aspects of clinical research. Future Forum plans include
further examining regulatory, administrative, and structural
barriers to the effective conduct of clinical research; developing
a vision for a stable, continuously funded clinical research
infrastructure in the United States; and considering strategies and
collaborative activities to facilitate more robust public
engagement in the clinical research enterprise. Table of Contents
Front Matter 1 Introduction 2 The State of Clinical Research in the
United States: An Overview 3 Challenges in Clinical Research 4
Clinical Trials in Cardiovascular Disease 5 Clinical Trials in
Depression 6 Clinical Trials in Cancer 7 Clinical Trials in
Diabetes 8 Building a Robust Clinical Trials Infrastructure
References Appendix A Agenda Appendix B Participant Biographies
The Food and Drug Administration (FDA) is tasked with ensuring the
safety and effectiveness of medicine. FDA's science base must be
strong enough to make certain that regulatory decisions are based
on the best scientific evidence. The IOM held a public workshop on
February 26, 2010, to examine the state of regulatory science and
to consider approaches for enhancing it.
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Hampstead
Diane Keaton, Brendan Gleeson, …
DVD
R66
Discovery Miles 660
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
|